Mechanisms of Chemoprevention, Antimutagenesis, and Anticarcinogenesis: An Overview

Chemoprevention of Cancer and DNA Damage by Dietary Factors

Volumn , Issue , 2009, Pages 57-72

  De Flora, Silvio ^a   Bennicelli, Carlo ^a   Battistella, Alessandra ^a   Bagnasco, Maria ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Anticarcinogenesis; Antimutagenesis; Chemoprevention; Mechanisms

Indexed keywords

EID: 84889370015     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626588.ch4     Document Type: Chapter

References (75)

1. De Flora, S., Izzotti, A., D'Agostini, F. and Balansky, R.M. (2001) Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis, 22, 999-1013.
2. De Flora, S., Izzotti, A., Albini, A., D'Agostini, F., Bagnasco, M. and Balansky, R.M. (2004) Antigenotoxic and cancer preventive mechanisms of N-acetyl-L-cysteine, in Cancer Chemoprevention, Promising Cancer Chemopreventive Agents, Vol. 1 (eds G.J. Kelloff, E.T. Hawk and C.C. Sigman), The Humana Press Inc., Totowa, NJ, pp. 37-67.
3. Izzotti, A., Balansky, R.M., Camoirano, A., Cartiglia, C., Longobardi, M., Tampa, E. and De Flora, S. (2003) Birth related genomic and transcriptional changes in mouse lung. Modulation by transplacental N-acetylcysteine. Mutation Research, 544, 441-449.
4. Balansky, R.M., Izzotti, A., Scatolini, L., D'Agostini, F. and De Flora, S. (1996) Induction by carcinogens and chemoprevention by N-acetylcysteine of adducts to mitochondrial DNA in rat organs. Cancer Research, 56, 1642-1647.
5. De Flora, S., Izzotti, A., Randerath, K., Randerath, E., Bartsch, H., Nair, J., Balansky, R.M., van Schooten, F.J., Degan, P., Fronza, G., Walsh, D. and Lewtas, J. (1996) DNA adducts in chronic degenerative diseases. Pathogenetic relevance and implications in preventive medicine. Mutation Research, 366, 197-238.
6. De Flora, S., Izzotti, A., Walsh, D., Degan, P., Petrilli, G.L. and Lewtas, J. (1997) Molecular epidemiology of atherosclerosis. The FASEB Journal, 11, 1021-1031.
7. Izzotti, A., Balansky, R.M., Cartiglia, C., Camoirano, A., Longobardi, M. and De Flora, S. (2003) Genomic and transcriptional alterations in mouse fetus liver after transplacental exposure to cigarette smoke. The FASEB Journal, 17, 1127-1129 (full text available online, April 22, 2003).
8. Izzotti, A., Saccà, S.M., Cartiglia, C. and De Flora, S. (2003) Oxidative DNA damage in the eye of glaucoma patients. The American Journal of Medicine, 114, 638-646.
9. De Flora, S., Quaglia, A., Bennicelli, C. and Vercelli, M. (2005) The epidemiological revolution of the 20th century. The FASEB Journal, 19, 892-897.
10. Last, J.M. (1986) Scope and methods of prevention, in Maxcy-Rosenau, Public Health and Preventive Medicine (eds J.M. Last, J. Chin, J.E. Fielding, A.L. Frank, J.C. Lashoff and R.B. Wallace), Appleton-Century-Crofts, Norwalk, CT, pp. 3-7.
11. Sporn, M.B. and Newton, D.L. (1979) Chemoprevention of cancer with retinoids. Federation Proceedings, 38, 2528-2534.
12. Kelloff, G.J. (2000) Perspectives on cancer chemoprevention research and drug development. Advances in Cancer Research, 78, 199-334.
13. De Flora, S., Balansky, R., Scatolini, L., Di Marco, C., Gasparini, L., Orlando, M. and Izzotti, A. (1996) Adducts to nuclear DNA and mitochondrial DNA as biomarkers in chemoprevention, in Principles of Chemoprevention (eds B.W. Stewart, D. McGregor and P. Kleihues), IARC Sciences Publication, No. 139, International Agency for Research on Cancer, Lyon, pp. 291-301.
14. Wattenberg, L.W. (1981) Inhibitors of chemical carcinogens, in Cancer: Achievements, Challenges and Prospects for the 1980s (eds J.H. Burchenal and H.F. Oettgen), Grune and Stratton, New York, NY, pp. 517-540.
15. Morse, M.A. and Stoner, G.D. (1993) Cancer chemoprevention: principles and prospects. Carcinogenesis, 14, 1737-1746.
16. Kada, T., Inoue, T. and Namiki, N. (1982) Environmental desmutagens and antimutagens, in Environmental Mutagenesis and Plant Biology (ed. E.J. Klekowski), Praeger, New York, NJ, pp. 137-151.
17. Ramel, C., Alekperov, U.K., Ames, B.N., Kada, T. and Wattenberg, L.W. (1986) Inhibitors of mutagenesis and their relevance to carcinogenesis. Mutation Research, 168, 47-65.
18. Boone, C.W., Kelloff, G.J. and Steele, V.E. (1992) Natural history of intraepithelial neoplasia in humans with implications for cancer chemopreventive strategy. Cancer Research, 52, 1651-1659.
19. Kelloff, G.J., Boone, C.W., Steele, V.E., Crowell, J.A., Lubet, R.A., Greenwald, P., Hawk, E.T., Fay, J.R. and Sigman, C.C. (1996) Mechanistic considerations in the evaluation of chemopreventive data, in Principles of Chemoprevention (eds B.W. Stewart, D. McGregor and P. Kleihues), IARC Sciences Publication, No. 139, International Agency for Research on Cancer, Lyon, pp. 203-219.
20. Steele, V.E. and Kelloff, G.J. (2005) Development of cancer chemopreventive drugs based on mechanistic approaches. Mutation Research, 591, 16-23.
21. De Flora, S. and Ramel, C. (1988) Mechanisms of inhibitors of mutagenesis and carcinogenesis. Classification and overview. Mutation Research, 202, 285-306.
22. De Flora, S., Zanacchi, P., Izzotti, A. and Hayatsu, H. (1991) Mechanisms of food-borne inhibitors of genotoxicity relevant to cancer prevention, in Mutagens in Food. Detection and Prevention (ed. H. Hayatsu), CRC Press, Boca Raton, FL, pp. 157-180.
23. De Flora, S., Izzotti, A. and Bennicelli, C. (1993) Mechanisms of antimutagenesis and anticarcinogenesis. Role in primary prevention, in Antimutagenesis and Anticarcinogenesis Mechanisms III (eds G. Bronzetti, H. Hayatsu, S. De Flora, M.D. Waters and D.M. Shankel), Plenum Press, New York, NY, pp. 1-16.
24. De Flora, S. (1998) Mechanisms of inhibitors of mutagenesis and carcinogenesis. Mutation Research, 402, 151-158.
25. De Flora, S., Izzotti, A., D'Agostini, F., Balansky, R.M., Noonan, D. and Albini, A. (2001) Multiple points of intervention in the prevention of cancer and other mutation related diseases. Mutation Research, 480-481, 9-22.
26. De Flora, S. and Ferguson, L.R. (2005) Overview of mechanisms of cancer chemopreventive agents. Mutation Research, 591, 8-15.
27. Kellof, J., Hawk, E.T. and Sigman, C.C. (eds) (2004) Promising Cancer Chemopreventive Agents, Vol. 1, Humana Press, Totowa, NJ.
28. IARC Handbooks of Cancer Prevention (2001) Sunscreens, International Agency for Research on Cancer, Vol. 5, World Health Organization, Lyon, France.
29. Ferguson, L.R. and De Flora, S. (2005) Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutation Research, 591, 24-33.
30. Greenwald, P., Kelloff, G.J., Boone, C.W. and McDonald, S.S. (1995) Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiology, Biomarkers & Prevention, 4, 691-702.
31. Bartsch, H., Oshima, H. and Pignatelli, B. (1988) Inhibitors of endogenous nitrosation. Mechanisms and implications in human cancer prevention. Mutation Research, 202, 307-324.
32. Commane, D., Hughes, R., Shortt, C. and Rowland, I. (2005) The potential mechanisms involved in the anticarcinogenic action of probiotics. Mutation Research, 591, 276-289.
33. De Flora, S., Scarfì, S., Izzotti, A., D'Agostini, F., Chang, C.-C., Bagnasco, M., De Flora, A. and Trosko, J.E. (2006) Induction by 7,12-dimethylbenz(a) anthracene of molecular and biochemical alterations in transformed human mammary epithelial stem cells, and protection by N-acetylcysteine. International Journal of Oncology, 29, 521-529.
34. Trosko, J.E., Chang, C.-C., Upham, B.L. and Tai, M.-H. (2005) The role of human adult stem cells and cell-cell communication in cancer chemoprevention and chemotherapy strategies. Mutation Research, 591, 187-197.
35. Hartman, P.E. and Shankel, D.M. (1990) Antimutagens and anticarcinogens: a survey of putative interceptor molecules. Environmental and Molecular Mutagenesis, 151, 145-182.
36. Pool-Zobel, B., Veeriah, S. and Böhmer, F.-D. (2005) Modulation of xenobiotic metabolising enzymes by anticarcinogen-focus on glutathione S-transferase and their role as targets of dietary chemoprevention in colorectal carcinogenesis. Mutation Research, 591, 74-92.
37. Yu, X. and Kensler, T. (2005) Nrf2 as a target for cancer chemoprevention. Mutation Research, 591, 93-102.
38. Talalay, P., Fahey, J.W., Holtzclaw, W.D., Prestera, T. and Zhang, Y. (1995) Chemoprotection against cancer by phase 2 enzyme induction. Toxicology Letters, 82-83, 173-179.
39. Izzotti, A., Bagnasco, M., Cartiglia, C., Longobardi, M., Camoirano, A., Tampa, E., Lubet, R.A. and De Flora, S. (2005) Modulation of multigene expression and proteome profiles by chemopreventive agents. Mutation Research, 591, 212-223.
40. Arimoto, S., Kan-yama, K., Rai, H. and Hayatsu, H. (1995) Inhibitory effect of hemin, clorophyllin and related pyrrole pigments on the mutagenicity of benzo[a] pyrene and its metabolites. Mutation Research, 345, 127-135.
41. Swanton, C. (2004) Cell-cycle targeted therapies. The Lancet Oncology, 5, 27-36.
42. Dragnev, K.H., Pitha-Rowe, I., Ma, Y., Petty, W.J., Sekula, D., Murphy, B., Rendi, M., Suh, N., Desai, N.B., Sporn, M.B., Freemantle, S.J. and Dmitrovsky, E. (2004) Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy. Clinical Cancer Research, 10, 2570-2577.
43. Fenech, M. (2001) The role of folic acid and vitamin B12 in genomic stability of human cells. Mutation Research, 475, 57-67.
44. Sram, R.J., Binkova, B., Lnenickova, Z., Solansky, I. and Dejmek, J. (2005) The impact of plasma folate levels of mothers and newborns on intrauterine growth retardation and birth weight. Mutation Research, 591, 302-310.
45. Naasani, I., Oh-Hashi, F., Oh-Hara, T., Feng, W.Y., Johnston, J., Chan, K. and Tsuruo, T. (2003) Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Research, 63, 824-830.
46. Belinsky, S.A., Klinge, D.M., Stidley, C.A., Issa, J.P., Herman, J.G., March, T.H. and Baylin, S.B. (2003) Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Research, 63, 7089-7093.
47. Izzotti, A., Bagnasco, M., Cartiglia, C., Longobardi, M., Balansky, R.M., Merello, A., Lubet, R.A. and De Flora, S. (2005) Chemoprevention of genome, transcriptome, and proteome alterations induced by cigarette smoke in rat lung. European Journal of Cancer, 41, 1864-1874.
48. Felsher, D.W. (2003) Cancer revoked: oncogenes as therapeutic targets. Nature Reviews. Cancer, 3, 375-380.
49. Jansen, B. and Zangemeister-Wittke, U. (2002) Antisense therapy for cancer-the time of truth. The Lancet Oncology, 3, 672-683.
50. Alyaqoub, F.S., Tao, L., Kramer, P.M., Steele, V.E., Lubet, R.A., Gunning, W.T. and Pereira, M.A. (2007) Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT). Carcinogenesis, 28, 124-129.
51. Hélène, C. (1991) Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. European Journal of Cancer, 27, 1466-1471.
52. Vogelstein, B. and Kinzler, K.W. (2001) Achilles' heel of cancer? Nature, 412, 865-866.
53. Zanesi, N., Pekarsky, Y. and Croce, C.M. (2005) A mouse model of the fragile gene FHIT: from carcinogenesis to gene therapy and cancer prevention. Mutation Research, 591, 103-109.
54. Esau, C.C. and Monia, B.P. (2007) Therapeutic potential for microRNAs. Advanced Drug Delivery Reviews, 59, 101-114.
55. Chen, T., Nines, R.G., Peschke, S.M., Kresty, L.A. and Stoner, G.D. (2004) Chemopreventive effects of a selective nitric oxide synthase inhibitor on carcinogen-induced rat esophageal tumorigenesis. Cancer Research, 64, 3714-3717.
56. Oshima, H., Tazawa, H., Sylla, B.S. and Sawa, T. (2005) Prevention of human cancer by modulation of chronic inflammatory processes. Mutation Research, 591, 110-122.
57. Steele, V.E., Holmes, C.A., Hawk, E.T., Kopelovich, L., Lubet, R.A., Crowell, J.A., Sigman, C.C. and Kelloff, G.J. (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiology, Biomarkers & Prevention, 8, 467-483.
58. Kundu, J.K. and Surh, Y.-J. (2005) Breaking the relay in deregulated cellular signal transduction as a rationale for chemoprevention with anti-inflammatory phytochemicals. Mutation Research, 591, 123-146.
59. Surh, Y.-J. (2003) Cancer chemoprevention with dietary phytochemicals. Nature Reviews. Cancer, 3, 768-780.
60. Weinstein, I.B. (1988) Strategies for inhibiting multistage carcinogenesis based on signal transduction pathways. Mutation Research, 202, 413-420.
61. Pierce, G.B. and Speers, W.C. (1988) Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Research, 48, 1996-2004.
62. Thorne, J. and Campbell, M.J. (2008) The vitamin D receptor in cancer. The Proceedings of the Nutrition Society, 67, 115-127.
63. D'Agostini, F., Izzotti, A., Balansky, R.M., Bennicelli, C. and De Flora, S. (2005) Modulation of apoptosis by chemopreventive agents. Mutation Research, 591, 173-186.
64. Folkman, J. (2000) Incipient angiogenesis. Journal of the National Cancer Institute, 92, 94-99.
65. Tosetti, F., Ferrari, N., De Flora, S. and Albini, A. (2002) "Angioprevention": angiogenesis is a common and key target for cancer chemopreventive agents. The FASEB Journal, 16, 2-14.
66. Cabebe, E. and Wakelee, H. (2007) Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab abd VEGFR tyrosine kinase inhibitor. Current Treatment Options in Oncology, 8, 15-27.
67. Lewis, J.S. and Jordan, V.C. (2005) Selective estrogen modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutation Research, 591, 247-263.
68. Raghow, S., Kuliyev, E., Steakley, M., Greenberg, N. and Steiner, M.S. (2000) Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model. Cancer Research, 60, 4093-4097.
69. Lu, L.-J.W., Anderson, K.E., Grady, J.J. and Nagamani, M. (2000) Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Research, 60, 4112-4121.
70. Buzdar, A. and Howell, A. (2001) Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clinical Cancer Research, 7, 2620-2623.
71. Ferguson, L.R. and Philpott, M. (2007) Cancer prevention by dietary bioactive components that target the immune response. Current Cancer Drug Targets, 7, 459-464.
72. Albini, A. and Sporn, M.B. (2007) The tumour microenvironment as a target for chemoprevention. Nature Reviews. Cancer, 7, 139-147.
73. Erez-Alon, N., Herkel, J., Wolkowicz, R., Ruiz, P.J., Waisman, A., Rotter, V. and Cohen, I.R. (1998) Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: generation of sequencespecific anti-DNA antibodies and protection from tumor metastasis. Cancer Research, 58, 5447-5452.
74. Stetler-Stevenson, W.G., Hewitt, R. and Corcoran, M. (1996) Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Seminars in Cancer Biology, 7, 147-154.
75. Lollini, P.L., DeGiovanni, C., Landuzzi, L., Nicoletti, G., Frabetti, F., Cavallo, F., Giovarelli, M., Forni, G., Modica, A., Modesti, A. et al. (1995) Transduction of genes coding for a histocompatibility (MHC) antigen and for its physiological inducer interferon-gamma in the same cell: efficient MHC expression and inhibition of tumor and metastasis growth. Human Gene Therapy, 6, 743-752.